News

Cancer Genetics to Provide Corporate Update at 16th Annual BIO CEO & Investor Conference in New York

By Jamie on February 10 2014

RUTHERFORD, NJ – February 10, 2014 – Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based diagnostics, announced today that Panna Sharma, President and Chief Executive Officer of Cancer Genetics, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, […]

Continue Reading

Cancer Genetics, Inc. and Roche Announce Expanded, Exclusive International Agreement to Provide Molecular Diagnostic Cancer Testing

By Italia on February 10 2014

CGI Will Be the Exclusive Provider of Molecular Diagnostic Cancer Testing for Roche Servicios in Central America and the Caribbean CGI Will Develop A Center of Excellence for Lung Cancer Testing Utilizing the FDA-Approved cobas® Platform RUTHERFORD, NJ (February  10, 2014): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, and Roche […]

Continue Reading

Cancer Genetics, Inc. Increases Access to its Full-Suite of Cancer Diagnostic Services through Agreement with Three Rivers Provider Network

By Italia on January 28 2014

CGI services are now accessible by an additional 15 million individuals in the U.S. RUTHERFORD, NJ (January 28, 2014): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, today announced the Company executed an agreement with health insurer Three Rivers Provider Network, Inc., one of the largest and fastest-growing preferred provider (“PPO”) […]

Continue Reading

Cancer Genetics, Inc. to Present at Two Investor Conferences in January

By Italia on January 8 2014

RUTHERFORD, NJ (January 8, 2014): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, today announced its CEO Panna Sharma will present at the following investor conferences:  7th Annual OneMedForumSF 2014, January 13-15, 2014 in San Francisco; CGI will present at 10:30 a.m. PT, Tuesday, January 14  Noble Financial’s 10th Annual Equity […]

Continue Reading

Cancer Genetics Appoints John Pappajohn Chairman of the Board of Directors

By Italia on January 6 2014

RUTHERFORD, NJ (January 6, 2014): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company, today announced that its board of directors appointed John Pappajohn as its new Chairman, effective January 6, 2014. Mr. Pappajohn is a recognized business leader and a pioneer in the venture capital industry. He has been involved in over 100 start-up companies, over 50 IPOs, and has served as […]

Continue Reading

Cancer Genetics, Inc. Strengthens Its Diagnostics Sales Team With Seasoned Industry Leader

By Italia on December 19 2013

Cancer Genetics, Inc. Strengthens Its Diagnostics Sales Team With Seasoned Industry Leader    RUTHERFORD, NJ (December 19, 2013): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, announces the addition of Christopher Mitton as Director of National Account Development and Sales Operations. Mr. Mitton will lead the national expansion of CGI’s Expand […]

Continue Reading

Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL) at the American Society of Hematology Annual Meeting in New Orleans

By Italia on November 25 2013

Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL) at the American Society of Hematology Annual Meeting in New Orleans RUTHERFORD, NJ (November 25, 2013): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, is presenting data from its research collaboration with Memorial Sloan-Kettering Cancer Center (“MSKCC”) […]

Continue Reading

Cancer Genetics, Inc. and Mayo Clinic Provide Update on their Joint Venture to Develop Next Generation Sequencing Company Focused on Areas of Critical Need in Oncology

By Italia on November 22 2013

  RUTHERFORD, NJ (November 22, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”) is jointly hosting an event today with the Mayo Clinic announcing the first projects to be pursued by their joint venture, which is set to develop targeted diagnostic panels that leverage next generation sequencing (“NGS”). CGI and Mayo Clinic formed […]

Continue Reading

Cancer Genetics, Inc. Featured in Two Key Latin American Genetics Conferences

By Italia on November 21 2013

The Company’s proprietary FHACT™ test for cervical cancer will be featured in genomic-focused workshops for leading oncologists, pathologists and cytogeneticists in Latin America RUTHERFORD, NJ (November 21, 2013): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, announces its participation in the third annual Latin American Human Genetics Congress and thirty-eighth annual National […]

Continue Reading

Cancer Genetics, Inc. Announces U.S. Launch of Its Proprietary DNA-Based Cervical Cancer Diagnostic Test, FHACT™

By Italia on November 18 2013

The FHACT™ test is focused on earlier detection and enables genomic guided decision making and triaging of cervical cancer caused by HPV. CGI worked on the research and development of this test based on a multi-year research grant with the National Cancer Institute and additional validations with global partners. The test will be made available […]

Continue Reading